ACCME/Disclosures. Risk of Gyne Ca in HBOC. Molecular basis of HBOC. Hereditary Ovarian and Breast Cancer Syndrome
|
|
- Debra Sanders
- 5 years ago
- Views:
Transcription
1 Hereditary Ovarian and Breast Cancer Syndrome C. Blake Gilks, MD Dept of Pathology Vancouver General Hospital University of British Columbia The USCAP requires that anyone in a position to influence ACCME/Disclosures or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner have, or have had, within the past 12 months, which relates to the content of this educational activity and creates a conflict of interest. Dr.Gilks declares no conflict(s) of interest Molecular basis of HBOC Mutations in BRCA1 or BRCA2 account for most cases; result in abnormalities in homologous recombination Other genes may also be mutated: BRIP1, RAD51C, RAD51D, PALB2, BARD1, TP53 etc. Risk of Gyne Ca in HBOC Ovarian ca risk approximately 35-45% for BRCA1 and 13-23% for BRCA2, by age 70 Endometrial Ca risk? (apparently not) 1
2 Ovarian Cancers in BRCA Mutation Carriers CONSISTENT: Epithelial carcinomas, more likely to be advanced stage, and high grade (grade 1 rarely reported). NOT borderline or mucinous VARIABLE: usually serous but proportion of endometrioid and clear cell, while low, varies CIMBA Study Data from ~6900 BRCA1 and BRCA2 mutation carriers Ovarian ca morphology same for BRCA1 and BRCA2 carriers More than 1000 ovarian carcinomas: 67% serous Mavaddat N et al. Cancer Epidemiol Biomarkers Prev 2012;21: CIMBA Study (con) Mucinous 1% Clear cell 1% Endometrioid 12% Other 19% Risch et al, Am J Hum Genet 2001;68:700 93% serous Shaw et al, Int J Gynecol Pathol 2002;21: % serous Why this difference? 2
3 Careful study of ovarian tumors often reveals two or even three or more cell types. Sternberg s Textbook of Pathology (2007) clear cell HG serous mucinous Implications of mixed carcinomas being common ovarian carcinoma subtypes are closely related differences between subtypes are unlikely to be relevant in 2007 ovarian carcinoma subtypes are not reproducibly diagnosable by pathologists 3
4 Implications of lack of reproducibility patients given different diagnoses in different centers results of studies on natural history provide conflicting results (e.g. clear cell carcinoma in NA/Europe vs Asia) impossible to move forward with good studies on molecular pathology or clinical trials of new treatments in 2016 What has changed? Review of 871 cases of ovarian carcinoma with classification by current criteria: % mixed 2. 41% of mixed carcinomas showed uniform immunophenotype throughout 3.Mixed ECa + CCC/ECa + LGSC accounted for most cases Mixed carcinomas of the ovary are rare, with the exception of the endometriosis-associated subtypes 4
5 Evolution of ovariancarcinomadiagnosis Table 1 HG serous clear cell mucinous Histotype diagnosis agreement between 2002 and 2014 (pathologist A): 52% Histotype diagnosis agreement between pathologist A and B (2014): 98% It is now possible for pathologists to routinely subclassify ovarian carcinomas into a small number of reproducible, clinically relevant groups 5
6 Germline BRCA mutations are seen in > 20% of HGS cancers Ovarian cancer histotypes Serous high grade Serous low grade Clear cell Endometrioid Mucinous 131 EOC cases 103 HGS cases 26 BRCA1/2 germline mutation carriers Summary of Results 26/103 (25%) high grade serous carcinomas had germline BRCA1 or BRCA2 mutations Results from Australian Ovarian Cancer Study Group 1001 patients with non-mucinous ovarian ca 14.1% of patients had germline BRCA1/2 mutations 16.6% of patients with serous ca had germline BRCA mutations 22.6% of patients with high-grade serous ca had germline mutations 6
7 Current BC recommendation High-grade serous carcinoma of re. HBOCS ovary/fallopian tube/peritoneum is associated with a BRCA1/2 mutation in over 20% of patients. We recommend that this patient be referred to the BCCA Hereditary Cancer Program. Prognosis of HGSC in patients with HBOC syndrome: 10 year overall survival 30% for non-carriers 25% for BRCA1 mutation carriers 35% for BRCA2 mutation carriers Candido-dos-Reis FJ et al. Clin Cancer Res 2015;21:652-7 Prevention Strategies HBOCS: RRBSO reduces deaths due to ovarian cancer by 80% (!?!) Case 1 Clinical History 33 year old, 10 cm complex pelvic mass, CA125 = 120 ku/l (norm 35) Laparotomy: left ovarian mass, 1 liter of bloody ascites, 3 cm nodule on right pelvic sidewall Frozen section diagnosis: granulosa cell tumor 7
8 8
9 Differential Diagnosis High-grade serous carcinoma (WT1 -) Grade 3 endometrioid carcinoma De-differentiated carcinoma/undifferentiated carcinoma (ER +, too cohesive/epithelial) Metastatic carcinoma (strong ER +, clinical) Less likely small cell carcinoma of hypercalcemic type (SMARCA4 +), malignant sex cord-stomal tumor (inhibin and FOXL2 -) 9
10 Immunohistochemistry 97% of HGSC are WT1 positive and 94% of HGSC are TP53 abnormal by IHC 10% of EC are WT1 positive and 14% are TP53 abnormal by IHC TP53 normal/wildtype TP53 abnormal/abe rrant/mutatio n-type WT1-286 EC (94%) 20 HGSC (6%) 48 EC (50%) 49 HGSC (50%) WT1+ 31 EC (27%) 84 HGSC (73%) 6 EC (0.5%) 1273 HGSC (99.5%) Final Diagnosis Grade 3 endometrioid carcinoma of the left ovary, with metastasis to left pelvic sidewall, cul-de-sac, and right pelvic sidewall Left fallopian tube, bladder peritoneum and omentum negative for malignancy Endometriosis in biopsy from right pelvic sidewall Abnormal MMR PMS2 deleted Case 2 86 year old with PMB Endometrial Bx: grade 3 carcinoma TAHBSO performed 10
11 11
12 Differential Diagnosis Primary fallopian tube ca metastatic to endometrium Primary endometrial ca metastatic to fallopian tube Independent primary tumors 60 cases of USC with fallopian tubes submitted in toto Fallopian tube mucosal involvement in 16 (27%) Bilateral tubal involvement in 9 of 16 (56%) 12
13 Final Diagnosis Serous carcinoma of endometrium with secondary involvement of mucosa of right fallopian tube, cervix (with invasion of cervical stroma), deep myometrial invasion, and extensive lymphvascular invasion Conclusions Accurate diagnosis of ovarian carcinoma histotype can allow for histotype specific referral of patients to the hereditary cancer program; patients with HGSC should be offered testing for HBOC Not all high grade tubo ovarian carcinomas are HGSC (but most are!) Fallopian tube mucosal involvement can be secondary/unrelated to HBOC 13
The Diagnostic Challenges of Low Grade and High Grade Tubo-Ovarian Serous Carcinomas. W Glenn McCluggage Belfast, Northern Ireland
The Diagnostic Challenges of Low Grade and High Grade Tubo-Ovarian Serous Carcinomas W Glenn McCluggage Belfast, Northern Ireland Enterprise Interest None OVARIAN SEROUS CARCINOMA (OSC) RECENT DEVELOPMENTS
More informationGynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationGynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationOvarian carcinoma classification. Robert A. Soslow, MD
Ovarian carcinoma classification Robert A. Soslow, MD soslowr@mskcc.org WHO classification Serous Mucinous Endometrioid Clear cell Transitional Squamous Mixed epithelial Undifferentiated Introduction Rationale
More informationHow to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens
How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens Wenxin Zheng, M.D. Professor of Pathology and Gynecology University of Arizona zhengw@email.arizona.edu http://www.zheng.gynpath.medicine.arizona.edu/index.html
More informationOvarian Clear Cell Carcinoma
Ovarian Clear Cell Carcinoma Rouba Ali-Fehmi, MD Professor of Pathology The Karmanos Cancer Institute, Wayne State University School of Medicine 50 year old woman with chief complaint of shortness of breath
More informationMPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?
MPH Quiz Case 1 Surgical Pathology from hysterectomy performed July 11, 2007 Final Diagnosis: Uterus, resection: Endometrioid adenocarcinoma, Grade 1 involving most of endometrium, myometrial invasion
More information5/26/2016. Pelvic Serous Carcinoma: 2014 W.H.O. Update. Outline of Talk. Changes to 2014 WHO system for pelvic serous tumors
Pelvic Serous Carcinoma: 2014 W.H.O. Update Outline of Talk Practical Implications for Pathologists Changes to 2014 WHO system for pelvic serous tumors High grade serous carcinoma versus low grade serous
More informationEpithelial Ovarian Cancer 8/2/2013. Tu-be or Not Tu-be: Is the Fallopian Tube the Source of Ovarian Cancer?
Tu-be or Not Tu-be: Is the Fallopian Tube the Source of Ovarian Cancer? Ann E. Smith Sehdev, MD Director, Center for Gynecologic Pathology Cascade Pathology, Portland, Oregon Ann E. Smith Sehdev has no
More information3 cell types in the normal ovary
Ovarian tumors 3 cell types in the normal ovary Surface (coelomic epithelium) the origin of the great majority of ovarian tumors (neoplasms) 90% of malignant ovarian tumors Totipotent germ cells Sex cord-stromal
More informationof 20 to 80 and subsequently declines [2].
- - According to the 2014 World Health Organization (WHO) classification and tumor morphology, primary ovarian tumors are subdivided into three categories: epithelial (60%), germ cell (30%), and sex-cord
More informationOvarian cancer: 2012 Update Srini Prasad MD Univ Texas MD Anderson Cancer Center
Ovarian cancer: 2012 Update Srini Prasad MD Univ Texas MD Anderson Cancer Center Ovarian cancer is not a single disease Ovarian Epithelial Tumors: Histological Spectrum* Type Frequency Histology High-Grade
More informationCurrent Concept in Ovarian Carcinoma: Pathology Perspectives
Current Concept in Ovarian Carcinoma: Pathology Perspectives Rouba Ali-Fehmi, MD Professor of Pathology The Karmanos Cancer Institute, Wayne State University School of Medicine Current Concept in Ovarian
More information3 cell types in the normal ovary
Ovarian tumors 3 cell types in the normal ovary Surface (coelomic epithelium) the origin of the great majority of ovarian tumors 90% of malignant ovarian tumors Totipotent germ cells Sex cord-stromal cells
More informationWhat s (new) and Important in Reporting of Uterine Cancers Katherine Vroobel The Royal Marsden
What s (new) and Important in Reporting of Uterine Cancers Katherine Vroobel The Royal Marsden Maastricht Pathology 2018 Wednesday 20 th June Endometrioid adenocarcinoma High grade carcinomas (common)
More informationACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI
USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone
More informationPacific Northwest Society of Pathologists Fall Meeting September 2015 Intraoperative Consultation in Gynecological Pathology: The Adnexal Mass
Pacific Northwest Society of Pathologists Fall Meeting September 2015 Intraoperative Consultation in Gynecological Pathology: The Adnexal Mass Julie Irving, MD Department of Pathology, University of British
More informationImmunohistochemistry on Fluid Specimens: Technical Considerations
Immunohistochemistry on Fluid Specimens: Technical Considerations Blake Gilks Dept of Pathology University of British Columbia, Vancouver, BC, Canada Disclosures None Learning Objectives At the end of
More informationTriage of Ovarian Masses. Andreas Obermair Brisbane
Triage of Ovarian Masses Andreas Obermair Brisbane Why Triage? In ovarian cancer, best outcomes for patients can be achieved when patients are treated in tertiary centres by a multidisciplinary team led
More informationPathology of Ovarian Tumours. Dr. Jyothi Ranganathan MD ( Path) AFMC Pune PDCC (Cytopathology) PGI Chandigarh
Pathology of Ovarian Tumours Dr. Jyothi Ranganathan MD ( Path) AFMC Pune PDCC (Cytopathology) PGI Chandigarh Outline Incidence Risk factors Classification Pathology of tumours Tumour markers Prevention
More informationInterpretation of p53 Immunostains. P53 Mutations are Ubiquitous in High Grade Serous Carcinoma. Diffuse strong positive nuclear staining
Stains for Tumor Classification p53 p16 WT1 HMGA2 P53 Mutations are Ubiquitous in High Grade Serous Carcinoma Source Ahmed et al Australian Ovarian Cancer Study Cancer Genome Atlas Research Network Cases
More informationDall istologia alla caratterizzazione biomolecolare
Il carcinoma ovarico: approccio multidisciplinare e prospettive terapeutiche Dall istologia alla caratterizzazione biomolecolare Anna Pesci Ospedale SC Don Calabria, Negrar anna.pesci@sacrocuore.it Ovarian
More informationOVARIAN CARCINOMA Immune Therapy. Antibodies to CA-125 (Ovarex) Vaccine therapy
OVARIAN CARCINOMA Immune Therapy Antibodies to CA-125 (Ovarex) Vaccine therapy OVARIAN CARCINOMA Targeted Therapy Bevacizumab (Avastin): GOG- 218 Anti-VEGF, angiogenesis inhibitor TLK 286 (Telcyta): Glutathione
More informationEDUCATIONAL COMMENTARY CA 125. Learning Outcomes
EDUCATIONAL COMMENTARY CA 125 Learning Outcomes Upon completion of this exercise, participants will be able to: discuss the use of CA 125 levels in monitoring patients undergoing treatment for ovarian
More informationGYNECOLOGIC MALIGNANCIES: Ovarian Cancer
GYNECOLOGIC MALIGNANCIES: Ovarian Cancer KRISTEN STARBUCK, MD ROSWELL PARK CANCER INSTITUTE DEPARTMENT OF SURGERY DIVISION OF GYNECOLOGIC ONCOLOGY APRIL 19 TH, 2018 Objectives Basic Cancer Statistics Discuss
More information6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017
Genetics 101 Hereditary Breast and Ovarian Cancer 2017 Rebecca Sutphen, MD, FACMG Professor, College of Medicine President & Chief Medical Officer INVASIVE CANCER GENETICALLY ALTERED CELL HYPERPLASIA DYSPLASIA
More informationCase 1. Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno
Case 1 Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno SAMO Interdisciplinary Workshop on Gynecological Tumors Lucern, October
More informationWork up of a Pelvic Mass
Work up of a Pelvic Mass Considerations from the north where primary care and CON clinic / GPO work interface Dr. Shannon Douglas, GPO Vanderhoof with support by Dr Margaret Smith and Dr. Ursula Lee Nov
More informationInstitute of Pathology First Faculty of Medicine Charles University. Ovary
Ovary Barrett esophagus ph in vagina between 3.8 and 4.5 ph of stomach varies from 1-2 (hydrochloric acid) up to 4-5 BE probably results from upward migration of columnar cells from gastroesophageal junction
More informationSection 1. Biology of gynaecological cancers: our current understanding
Section 1 Biology of gynaecological cancers: our current understanding Chapter 1 Morphological sub-types of ovarian carcinoma: new developments and pathogenesis W Glenn McCluggage 1 Introduction In most
More informationGYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer
GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome
More informationMousa. Najat kayed &Renad Al-Awamleh. Nizar Alkhlaifat
6 Mousa Najat kayed &Renad Al-Awamleh Nizar Alkhlaifat P a g e 1 This sheet written based on record 13 on website Cover slide( 95-117 ) No need to go back to slide FALLOPIAN TUBE PATHOLOGY In general fallopian
More informationEvaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes
Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes Melinda S. Yates, PhD Department of Gynecologic Oncology & Reproductive Medicine University
More informationPathology of the female genital tract
Pathology of the female genital tract Common illnesses of the female genital tract Before menarche Developmental anomalies Tumors (ovarial teratoma) Amenorrhea Fertile years PCOS, ovarian cysts Endometriosis
More informationBRCAplus. genetic testing for hereditary breast cancer
BRCAplus genetic testing for hereditary breast cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer familial
More informationThe role of immunohistochemistry in surgical pathology of the uterine corpus and cervix
The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
More informationKey Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer
Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program Lead, Kaiser Permanente Northern California
More informationPatologia Molecular del Carcinoma de Ovario
Curso de Patologia Molecular XXVI Congreso Nacional de la SEAP Cadiz Patologia Molecular del Carcinoma de Ovario Jaime Prat Barcelona Ovarian Epithelial Tumors WHO 1999 and 2003 Serous Mucinous Endometrioid
More informationDisclosures/Conflict of Interest. Learning Objectives 10/2/2015. Opportunistic salpingectomy for ovarian cancer prevention Jessica N McAlpine, UBC
Opportunistic salpingectomy for ovarian cancer prevention Jessica N McAlpine, UBC Disclosures/Conflict of Interest No conflicts of interest to declare No discussion re off label use and/or investigational
More informationFemale Genital Tract Lab. Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan
Female Genital Tract Lab Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan Ovarian Pathology A 20-year-old female presented with vague left pelvic pain. Pelvic exam revealed
More informationCase presentation 04/13/2017. Genomic/morphological classification of endometrial carcinoma
Genomic/morphological classification of endometrial carcinoma Robert A. Soslow, MD soslowr@mskcc.org architecture.about.com Case presentation 49 year old woman with vaginal bleeding Underwent endometrial
More informationEndometrial Cancer. Incidence. Types 3/25/2019
Endometrial Cancer J. Anthony Rakowski DO, FACOOG MSU SCS Board Review Coarse Incidence 53,630 new cases yearly 8,590 deaths yearly 4 th most common malignancy in women worldwide Most common GYN malignancy
More informationRESEARCH COMMUNICATION
RESEARCH COMMUNICATION Clinicopathologic Analysis of Women with Synchronous Primary Carcinomas of the Endometrium and Ovary: 10- Year Experience from Chiang Mai University Hospital Jiraprapa Natee 1 *,
More informationKey Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer. HBOC related genes. I have nothing to disclose
Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program I have nothing to disclose Key Recommendations
More informationInternational Society of Gynecological Pathologists Symposium 2007
International Society of Gynecological Pathologists Symposium 2007 Anais Malpica, M.D. Department of Pathology The University of Texas M.D. Anderson Cancer Center Grading of Ovarian Cancer Histologic grade
More information3/28/2017. Disclosure of Relevant Financial Relationships. Clinical History. Pathology
Disclosure of Relevant Financial Relationships Monalisa Sur MBBS, FCPath(S.A), MMED(WITS), FRCPath(U.K), FRCP( C) Professor, Department of Pathology and Molecular Medicine Division of Anatomical Pathology
More informationCancer arising from Endometriosis and Its Clinical implications
Cancer arising from Endometriosis and Its Clinical implications 1) Nezhat F, Cohen C, Rahaman J, Gretz H, Cole P, Kalir T. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign
More informationHereditary Cancer Products
Hereditary Products Integrated BRACAnalysis (BRCA1 and BRCA2 sequencing and large rearrangement testing (BART)), covered when: PERSONAL HISTORY of Breast (must meet at least 1) Diagnosed
More informationL/O/G/O. Ovarian Tumor. Xiaoyu Niu Obstetrics and Gynecology Department Sichuan University West China Second Hospital
L/O/G/O Ovarian Tumor Xiaoyu Niu Obstetrics and Gynecology Department Sichuan University West China Second Hospital Essentials classification of ovarian tumor clinical manifestation of ovarian tumor metastatic
More informationLow-grade serous neoplasia. Robert A. Soslow, MD
Low-grade serous neoplasia Robert A. Soslow, MD soslowr@mskcc.org Outline Orientation Ovarian tumor overview Non serous borderline tumors Serous borderline tumors Clinical summary Morphologic description
More informationBases biológicas del cáncer de ovario en el siglo XXI
Bases biológicas del cáncer de ovario en el siglo XXI Iñigo Espinosa, M.D. Clínica Universidad de Navarra Epithelial Ovarian Tumors WHO 1973-2014 Serous Mucinous Endometrioid Clear cell Transitional Squamous
More informationOvarian Cancer What you need to know
Ovarian Cancer What you need to know www.ovarian.org.uk Contents Your body and your ovaries What is ovarian cancer? Your body and your ovaries 3 What is ovarian cancer? 3 Not one disease, but many 4 The
More informationCharacterizing Adnexal Masses: Pearls and Pitfalls 20 th Annual Summer Practicum SCBT-MR Jackson Hole August 11, 2010
Characterizing Adnexal Masses: Pearls and Pitfalls 20 th Annual Summer Practicum SCBT-MR Jackson Hole August 11, 2010 Evan S. Siegelman MD University of Pennsylvania Medical Center Adnexal Masses: Pearls
More informationGenetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?
More informationMyriad Financial Assistance Program (MFAP)
Myriad Financial Assistance Program (MFAP) MEDICAL CRITERIA Hereditary Cancer Products The Myriad Financial Assistance Program offers aid to patients who meet specific financial and medical requirements.
More informationStaging and Treatment Update for Gynecologic Malignancies
Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths
More informationScreening and prevention of ovarian cancer
Chapter 2 Screening and prevention of ovarian cancer Prevention of ovarian carcinoma Oral contraceptive pills Use of oral contraceptive pills (OCPs) has been associated with a significant reduction in
More informationUTERINE SARCOMA EXAMPLE OF A UTERINE SARCOMA USING PROPOSED TEMPLATE
UTERINE SARCOMA EXAMPLE OF A UTERINE SARCOMA USING PROPOSED TEMPLATE Case: Adenosarcoma with heterologous elements and stromal overgrowth o TAH, BSO, omentectomy, staging biopsies of cul-de-sac, bladder
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More informationGYNplus. genetic testing for hereditary ovarian and/or uterine cancer
GYNplus genetic testing for hereditary ovarian and/or uterine cancer What Are the Causes of Hereditary Ovarian and Uterine Cancer? uterine cancer ovarian cancer sporadic 70-80% hereditary 5% Lynch syndrome
More informationOppgave: MED5600_OPPGAVE04_V18_ORD
Side 23 av 63 Oppgave: MED5600_OPPGAVE04_V18_ORD Del 1: Sofie, 38 years, para1, comes to your office complaining about dyspareunia and spotting she has recently observed on several occasions, unrelated
More informationFocus on... Ovarian cancer. HE4 & ROMA score
Focus on... Ovarian cancer HE4 & ROMA score Ovarian cancer in the world* Accounting for around 4% of all cancers diagnosed in women The estimated World age-standardised incidence rate for the more developed
More informationPredictive and Diagnostic Testing for Cancer in Women. Aparna Rajadhyaksha MD
Predictive and Diagnostic Testing for Cancer in Women Aparna Rajadhyaksha MD Hereditary Cancer s in Women BRCA1 &2 Other Breast Cancer Genes Li Fraumeni PTEN CHEK2 BRCA1&2 t BRCA1 is part of a complex
More informationProtocol for the Examination of Specimens From Patients With Primary Tumors of the Ovary, Fallopian Tube, or Peritoneum
Protocol for the Examination of Specimens From Patients With Primary Tumors of the Ovary, Fallopian Tube, or Peritoneum Version: OvaryFallopian 1.1.0.0 Protocol Posting Date: August 2018 Includes ptnm
More informationBiology Response Controversies and Advances
Biology Response Controversies and Advances in BRCA related ovarian cancer Lessons learned and future directions Michael Friedlander The Prince of Wales Hospital and Royal Hospital for Women Sydney BREAST-CANCER
More informationProtocol for the Examination of Specimens From Patients With Primary Tumors of the Ovary, Fallopian Tube, or Peritoneum
Protocol for the Examination of Specimens From Patients With Primary Tumors of the Ovary, Fallopian Tube, or Peritoneum Version: Protocol Posting Date: June 2017 Includes ptnm requirements from the 8 th
More informationInherited Ovarian Cancer Diagnosis and Prevention
Inherited Ovarian Cancer Diagnosis and Prevention Dr. Jacob Korach - Deputy director Gynecologic Oncology (past chair - Israeli Society of Gynecologic Oncology) Prof. Eitan Friedman - Head, Oncogenetics
More informationFast Facts: Ovarian Cancer
Fast Facts Fast Facts: Ovarian Cancer Christina Fotopoulou MD PhD Consultant Gynaecological Oncologist Queen Charlotte s and Chelsea Hospital London, UK Thomas J Herzog MD Professor of Obstetrics and Gynecology
More informationClinical Implications for Intervention
Hereditary Breast and Ovarian Cancer Syndromes: Clinical Implications for Intervention Muhieddine Seoud, MD, FACOG, FACS American University of Beirut Medical Center MEMAGO 1rst meeting, Ankara, March
More informationACCME/Disclosures. Case 4 USCAP Pulmonary Panel Case 4 History
Case 4 USCAP Pulmonary Panel 2016 Andrew Churg, MD Department of Pathology Vancouver General Hospital & University of British Columbia Vancouver, BC achurg@mail.ubc.ca. ACCME/Disclosures The USCAP requires
More informationRicombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD
Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies
More informationGynaecological Malignancies
Gynaecological Malignancies Dr Rodney Itaki Lecturer Anatomical Pathology Discipline University of Papua New Guinea Division of Pathology School of Medicine & Health Sciences Overview Genital tract tumors
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-13-1-0421 TITLE: The Fanconi Anemia BRCA Pathway as a Predictor of Benefit from Bevacizumab in a Large Phase III Clinical Trial in Ovarian Cancer PRINCIPAL INVESTIGATOR: Elizabeth
More informationGenetic Testing: who, what, why?
Genetic Testing: who, what, why? Gina Westhoff MD LMG Gynecologic Oncology March 16, 2019 Disclosures Speaker for Merck (unrelated to today s topic) Objectives Determine who should undergo genetic risk
More informationGENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER. Dr Abhijit Dixit. Family Health Clinical Genetics
GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review
More informationUnexpected Gynecologic Findings at Laparotomy. Susan A. Davidson, MD University of Colorado, Denver School of Medicine
Unexpected Gynecologic Findings at Laparotomy Susan A. Davidson, MD University of Colorado, Denver School of Medicine Adnexal Mass: Gyn Etiologies Uterine Leiomyomas Pregnancy Malignancy Tubal Pregnancy
More informationArticle begins on next page
Pseudopapillary Granulosa Cell Tumor: A Case of This Rare Subtype Rutgers University has made this article freely available. Please share how this access benefits you. Your story matters. [https://rucore.libraries.rutgers.edu/rutgers-lib/50622/story/]
More informationUW359 Ovary 3c 3 Serous Recurrent 68 BRCA1 816delGT BRCA1 del exon 1-2. UW417 Ovary 3c 3 Serous Primary 38 BRCA1 1675delA
Supplementary Table 1. Cases with deleterious germline mutations, somatic HR mutations, and somatic PTEN mutations. ID Site Stage Grade Histology Tumor Age Germline mutation(s) a Somatic HR mutation(s)
More informationCASO 1. Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA.
CASO 1 Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA. ASSESSMENT OF PRIMARY ORIGIN IN PATIENTS WITH A PREVIOUS HISTORY OF CANCER Primary Tumor T1 T5 T6 T13
More information64 YO lady THBSO for prolapse At gross : A 3 cm endometrial polyp in the fundus
Case 6 64 YO lady THBSO for prolapse At gross : A 3 cm endometrial polyp in the fundus Numerous irregular, large glands with leaf-like pattern Large glands with broad-based papillary infolding into the
More informationModern Pathology (2015) 28,
2015 USCAP, Inc All rights reserved 0893-3952/15 $32.00 1101 Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer
More informationCA125 in the diagnosis of ovarian cancer: the art in medicine
CA125 in the diagnosis of ovarian cancer: the art in medicine Dr Marcia Hall Consultant Medical Oncology Mount Vernon Cancer Centre Hillingdon Hospital Wexham Park Hospital Epidemiology Ovarian cancer
More information3/24/2017. Disclosure of Relevant Financial Relationships. Mixed Epithelial Endometrial Carcinoma. ISGyP Endometrial Cancer Project
Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME disclose any relevant financial relationship
More informationAdenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms
Cobb et al. Gynecologic Oncology Research and Practice (2015) 2:1 DOI 10.1186/s40661-015-0008-z REVIEW Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment
More informationShina Oranratanaphan, Tarinee Manchana*, Nakarin Sirisabya
Comparison of Synchronous Endometrial and Ovarian Cancers versus Primary with Metastasis RESEARCH COMMUNICATION Clinicopathologic Variables and Survival Comparison of Patients with Synchronous Endometrial
More informationTop Tips for Gynaecological Ultrasound. Catherine Kirkpatrick Consultant Sonographer Dublin Oct 2018
Top Tips for Gynaecological Ultrasound Catherine Kirkpatrick Consultant Sonographer Dublin Oct 2018 We can all scan a pelvis so what can we do to improve? Uterus, endometrium and ovaries, got it covered!
More informationMolecular Subtyping of Endometrial Cancer: A ProMisE ing Change
Molecular Subtyping of Endometrial Cancer: A ProMisE ing Change Charles Matthew Quick, M.D. Associate Professor of Pathology Director of Gynecologic Pathology University of Arkansas for Medical Sciences
More informationSCREENING FOR OVARIAN CANCER DR MACİT ARVAS
SCREENING FOR OVARIAN CANCER DR MACİT ARVAS Ovarian cancer is the leading cause of death from gynecologic malignancy In 2008, ovarian cancer was the seventh common cancer in women worldwide There were
More informationImportanza del test genetico nel carcinoma mammario ed ovarico
Importanza del test genetico nel carcinoma mammario ed ovarico Lorena Incorvaia Azienda Ospedaliera Universitaria Policlinco «P.Giaccone» Palermo UOC Oncologia Medica Ovarian Cancer Breast Cancer The range
More informationWELCOME. Taking Care of Your Health. April 30, 8 am to noon
WELCOME Taking Care of Your Health April 30, 8 am to noon Cancer: Know Your Risk Emily Kuchinsky, MS, CGC, Certified Genetic Counselor Sporadic Cancer Lifetime Probability- Women Family Cluster Risk factors
More informationMucinous Tumors of the Ovary Beirut, Lebanon. Anaís Malpica, M.D. Professor Department of Pathology
Mucinous Tumors of the Ovary Beirut, Lebanon Anaís Malpica, M.D. Professor Department of Pathology Primary Mucinous Tumors of the Ovary Cystadenoma Borderline (Tumor of Low Malignant Potential/Atypical
More informationClinical History USCAP Specialty Conference. Gynecologic Pathology Case 3
2010 USCA Specialty Conference Gynecologic athology Case Kathleen R. Cho, M.D. Department of athology Clinical History 46 yo woman presented with bilateral ovarian masses and elevated CA-125 TAH/BSO, pelvic
More informationDisclosure. Gynecologic Cancer Genetics. Audience response. Audience response. What was the result? 47%
Disclosure Cancer Genetics I have served as a moderator for an advisory board to Genentech Lee-may Chen, M.D. Professor Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Obstetrics and
More informationSarah Burton. Lead Gynae Oncology Nurse Specialist Cancer Care Cymru
Sarah Burton Lead Gynae Oncology Nurse Specialist Cancer Care Cymru Gynaecological Cancers Cervical Cancers Risk factors Presentation Early sexual activity Multiple sexual partners Smoking Human Papiloma
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More informationHuman epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts
Human epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts Ovarian cancer is diagnosed annually in more than 200,000 women worldwide, with
More informationHistopathological Study of Spectrum of Lesions Seen in Surgically Resected Specimens of Fallopian Tube
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2016/613 Histopathological Study of Spectrum of Lesions Seen in Surgically Resected Specimens of Fallopian Tube Pratima
More informationBiomarker for Response and Resistance in Ovarian Cancer
2016 대한부인종양학회제 31 차춘계학술대회 New Trends in Translational Research Biomarker for Response and Resistance in Ovarian Cancer Shin-Wha Lee, M.D., Ph.D. Department of Obstetrics and Gynecology ASAN Medical Center
More information2015 EUROPEAN CANCER CONGRESS
2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th
More informationSerous Tubal Intraepithelial Carcinoma in a Japanese Woman with a Deleterious BRCA1 Mutation
Japanese Journal of Clinical Oncology Advance Access published April 9, 2014 Jpn J Clin Oncol 2014 doi:10.1093/jjco/hyu035 Case Report Serous Tubal Intraepithelial Carcinoma in a Japanese Woman with a
More information